Astellas Pharma Inc. (ALPMY)
OTC: ALPMY
· Real-Time Price · USD
11.33
0.15 (1.34%)
At close: Aug 15, 2025, 3:58 PM
11.30
-0.26%
After-hours: Aug 15, 2025, 03:58 PM EDT
Astellas Pharma Income Statement
Financials in JPY. Fiscal
year is
April - March.
Fiscal Year | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
Revenue | 459.29B | 517.41B | 462.5B | 473.12B | 414.6B | 421.93B | 392.15B | 374.99B | 354.25B | 402.18B | 380.39B | 381.79B | 303.87B | 340.63B | 325.52B | 326.14B | 308.62B | 325.43B | 308.51B | 306.97B |
Cost of Revenue | 76.86B | 98.52B | 82.69B | 91.14B | 105.88B | 108.34B | 99.08B | 78.02B | 71.54B | 83.63B | 72B | 99.61B | 66.95B | 77.23B | 68.92B | 68.19B | 64.8B | 68.19B | 59.9B | 59.65B |
Gross Profit | 382.44B | 418.88B | 379.81B | 381.99B | 308.73B | 313.6B | 293.07B | 296.98B | 282.71B | 318.55B | 308.39B | 282.18B | 236.92B | 263.4B | 256.6B | 257.95B | 243.82B | 257.24B | 248.62B | 247.31B |
Operating Income | 63.52B | -116.19B | 63.17B | 53.32B | 37.72B | 39.71B | 36.44B | 64.2B | 53.34B | 88.65B | 88.66B | 54.77B | 26.14B | 68.9B | 62.46B | 62.53B | 46.88B | 72.59B | 26.3B | 60.84B |
Interest Income | n/a | n/a | n/a | 162M | 4.12B | 1.18B | 2.37B | 3.78B | 2.44B | 1.17B | 3.56B | 927M | 3.84B | 417M | 432M | 1.46B | 5.1B | 3.06B | 3.07B | 379M |
Pretax Income | 60.55B | -118.36B | 38.55B | 50.49B | -45.96B | 17.54B | 6.25B | 46.16B | -47.77B | 60.16B | 87.37B | 31.33B | -8.97B | 76.59B | 53.24B | 35.54B | -19.65B | 75.14B | 28.85B | 60.24B |
Net Income | 74.9B | -97.66B | 35.91B | 37.6B | -33.28B | 14.51B | -1.46B | 33.13B | -46.13B | 48.41B | 71.62B | 24.81B | -8.41B | 60.88B | 40.92B | 30.69B | -12.33B | 60.08B | 22.43B | 50.41B |
Selling & General & Admin | 211.32B | 225.31B | 199.53B | 206.88B | 193.15B | 199.5B | 179.28B | 168.18B | 159.29B | 163.02B | 154.56B | 153.4B | 142.42B | 135.91B | 133.4B | 137.11B | 141.27B | 120.91B | 121.36B | 120.78B |
Research & Development | 76.23B | 79.09B | 85.51B | 86.82B | 77.85B | 74.39B | 77.36B | 64.59B | 70.08B | 66.88B | 65.17B | 74.01B | 68.36B | 58.59B | 60.75B | 58.31B | 55.67B | 57.12B | 54.41B | 57.29B |
Other Expenses | 31.37B | 230.68B | 31.6B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 318.92B | 535.08B | 316.64B | 331.33B | 271B | 273.89B | 256.63B | 232.77B | 229.37B | 229.9B | 219.73B | 227.4B | 210.78B | 194.5B | 194.14B | 195.42B | 196.94B | 184.64B | 222.56B | 186.5B |
Interest Expense | n/a | n/a | n/a | 324M | 4.19B | 2.83B | 2.27B | 2.72B | 2.07B | 2.8B | 1.51B | 2.4B | 675M | 1.3B | 1.25B | 1.72B | 589M | 520M | 271M | 956M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 395.77B | 633.6B | 399.33B | 422.47B | 376.88B | 382.22B | 355.71B | 310.79B | 300.91B | 313.53B | 291.73B | 327.02B | 277.73B | 271.73B | 263.06B | 263.62B | 261.74B | 252.83B | 282.45B | 246.15B |
Income Tax Expense | -14.34B | -20.7B | 2.64B | 12.89B | -15.38B | 2.8B | 6.79B | 13.72B | -1.75B | 11.35B | 17.18B | 6.87B | -2.11B | 17.43B | 12.33B | 5.14B | -6.58B | 15.06B | 6.43B | 9.82B |
Shares Outstanding (Basic) | 1.82B | 1.79B | 1.8B | 1.8B | 1.79B | 1.79B | 1.79B | 1.79B | 1.81B | 1.82B | 1.82B | 1.83B | 1.84B | 1.85B | 1.85B | 1.85B | 1.86B | 1.86B | 1.86B | 1.86B |
Shares Outstanding (Diluted) | 1.82B | 1.79B | 1.8B | 1.8B | 1.79B | 1.8B | 1.79B | 1.8B | 1.81B | 1.82B | 1.82B | 1.83B | 1.84B | 1.85B | 1.85B | 1.85B | 1.86B | 1.86B | 1.86B | 1.86B |
EPS (Basic) | 41.83 | -54.57 | 20.06 | 20.94 | -18.56 | 8.09 | -0.81 | 18.46 | -25.49 | 26.56 | 39.30 | 13.60 | -4.57 | 32.86 | 22.09 | 16.56 | -6.64 | 32.33 | 12.07 | 27.12 |
EPS (Diluted) | 41.19 | -54.57 | 19.97 | 20.94 | -18.56 | 8.06 | -0.81 | 18.42 | -25.49 | 26.55 | 39.28 | 13.59 | -4.57 | 32.84 | 22.07 | 16.55 | -6.64 | 32.33 | 12.07 | 27.12 |
EBITDA | 101.78B | 126.06B | 88.05B | 103.59B | 4.17B | 67.13B | 46.57B | 72.81B | -22.79B | 85.56B | 113.16B | 70.95B | 11.24B | 101.14B | 73.45B | 55.69B | 65.45B | 90.74B | 44.24B | 78.84B |
EBIT | 54.1B | 74.89B | 38.03B | 54.99B | -44.48B | 20.14B | 7.6B | 49.57B | -45.8B | 62.56B | 90.31B | 34.08B | -9.84B | 79.62B | 54.51B | 37.55B | -18.31B | 75.66B | 29.12B | 61.19B |
Depreciation & Amortization | 47.68B | 51.16B | 50.02B | 50.27B | 48.64B | 46.98B | 38.97B | 23.24B | 23.02B | 23B | 22.85B | 36.87B | 21.08B | 21.52B | 18.94B | 18.14B | 18.56B | 18.15B | 17.94B | 18B |